Mazor Robotics (NASDAQ:MZOR) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.
A number of other equities analysts have also recently commented on the stock. Zacks Investment Research upgraded shares of Mazor Robotics from a “sell” rating to a “hold” rating in a research report on Thursday, November 16th. TheStreet upgraded shares of Mazor Robotics from a “d” rating to a “c-” rating in a research report on Wednesday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Mazor Robotics in a research report on Tuesday, November 7th. Ladenburg Thalmann Financial Services set a $67.00 target price on shares of Mazor Robotics and gave the stock a “buy” rating in a research report on Monday, October 30th. Finally, Barclays cut shares of Mazor Robotics from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $55.00 to $34.00 in a research report on Thursday, October 19th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company’s stock. Mazor Robotics presently has an average rating of “Hold” and an average price target of $39.83.
Shares of Mazor Robotics (MZOR) traded down $0.32 during trading hours on Friday, reaching $57.83. 310,115 shares of the company were exchanged, compared to its average volume of 547,292. Mazor Robotics has a one year low of $20.50 and a one year high of $65.97.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.